Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Upgraded by Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.

A number of other equities analysts have also recently issued reports on TVRD. Chardan Capital started coverage on Tvardi Therapeutics in a report on Tuesday, October 20th. They issued a “buy” rating for the company. Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a research report on Wednesday, July 8th. Lucid Cap Mkts raised Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. BTIG Research dropped their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Piper Sandler upgraded Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.40.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ:TVRD opened at $0.94 on Friday. The firm has a market capitalization of $12.54 million, a PE ratio of -0.34 and a beta of 0.38. Tvardi Therapeutics has a 52-week low of $0.92 and a 52-week high of $5.69. The firm has a fifty day moving average of $1.48 and a 200 day moving average of $2.40.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, sell-side analysts forecast that Tvardi Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Trading of Tvardi Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $63,000. BlackRock Inc. bought a new position in Tvardi Therapeutics during the 2nd quarter worth approximately $181,000. Finally, GSA Capital Partners LLP bought a new position in Tvardi Therapeutics during the 2nd quarter worth approximately $34,000. 44.66% of the stock is owned by institutional investors.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.